Patent Number: 6,252,077

Title: 1-(N'-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands

Abstract: Disclosed are compounds of the formula ##STR1## or the pharmaceutically acceptable salts thereof wherein the 6-membered A ring may be optionally substituted with up to four groups independently selected from halogen, hydroxy, lower alkyl, or lower alkoxy; Ar represents optionally substituted aryl or heteroaryl Z represents carbon or nitrogen provided that where Z is carbon, R.sub.11 represents hydrogen, halogen, hydroxy, lower alkyl, or lower alkoxy, or phenyl optionally substituted with one or two groups selected from hydrogen, halogen, hydroxy, lower alkyl, or lower alkoxy; and where Z is nitrogen, R.sub.11 represents an electron pair; R.sub.5 is hydrogen or lower alkyl; m represents an integer; n is 0, or an integer; R.sub.12 and R.sub.13 independently represent lower alkyl; CR'R" represent a methylene group optionally substituted with lower alkyl; and k is 1, which compounds are useful in treating various neuropsychological disorders including, for example, schizophrenia, dementia, depression, anxiety, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

Inventors: He; Xiao-shu (Branford, CT), de Costa; Brian (Branford, CT), Wasley; Jan W. F. (Guilford, CT)

Assignee: Neurogen Corporation

International Classification: C07D 209/00 (20060101); C07D 403/12 (20060101); C07D 209/44 (20060101); C07D 217/00 (20060101); C07D 217/22 (20060101); C07D 401/00 (20060101); C07D 403/00 (20060101); C07D 401/12 (20060101); C07D 209/40 (); C07D 401/12 (); C07D 403/12 ()

Expiration Date: 06/26/2018